Free And Open: The Next Wave In Clinical Trial Data?
Executive Summary
Transparency is an issue that continues to pose reputational challenges for biopharma. A key flashpoint is the disclosure – under open access rules – of clinical trial data in a climate of mounting therapeutic competition. Still, some industry players are pushing the boundaries around open access. Project Data Sphere, a non-profit group backed by the CEO Roundtable on Cancer, is taking advantage of new IT platforms and the rich target potential in discovery science to press for a larger industry consensus around new ways to release high-value data embedded in years of trials, all for the benefit of cancer patients.
You may also be interested in...
Big Data And The FDA: To Mine The Value, First Mind The Gaps
INFORMED is a new initiative at the FDA to incubate new ideas in applying big data to boost the scientific, economic and social returns from the regulation of drugs and medical devices, with a particular focus on cancer.
Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?
2018 will be a time of transition in health care, when biopharma’s counterparts in adjacent industry segments scale up in a radical redesign of their traditional business models. Biopharma is not moving as quickly, and it confronts a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.
Tracking Transparency In Clinical Trials: Progress But To What Standard?
A second survey by the independent NGO Bioethics International shows significant improvement in big pharma’s willingness to share data on clinical trials for important novel drugs. Expectations for further progress remain high, but consensus around a globally consistent, measurable standard is still a long slog.